**Background of GSDMA Antibodies**
GSDMA (Gasdermin A) is a member of the gasdermin protein family, which plays a critical role in pyroptosis—a lytic, inflammatory form of programmed cell death. GSDMA is encoded by the *GSDMA* gene located on human chromosome 17q21. It is predominantly expressed in epithelial tissues, such as the skin, gastrointestinal tract, and respiratory system. Like other gasdermins, GSDMA contains a pore-forming N-terminal domain and an autoinhibitory C-terminal domain. Upon proteolytic cleavage (e.g., by inflammatory caspases or granzymes), the N-terminal fragment oligomerizes to form pores in the cell membrane, triggering pyroptosis and releasing pro-inflammatory cytokines.
GSDMA antibodies are tools used to detect and study the expression, activation, and function of GSDMA in physiological and pathological contexts. Research suggests GSDMA may act as a tumor suppressor in certain cancers, with reduced expression linked to poor prognosis. Conversely, dysregulated GSDMA has been implicated in inflammatory diseases and epithelial barrier dysfunction. Antibodies targeting specific epitopes (e.g., full-length vs. cleaved forms) enable investigations into its activation mechanisms, tissue-specific roles, and therapeutic potential. Challenges include ensuring antibody specificity due to homology among gasdermin family members (e.g., GSDMB, GSDMD). Validations using knockout models or functional assays are critical. Current applications span cancer biology, immunology, and studies of mucosal homeostasis, highlighting GSDMA’s dual role in inflammation and cancer.